JP2021523169A5 - - Google Patents
Info
- Publication number
- JP2021523169A5 JP2021523169A5 JP2020563505A JP2020563505A JP2021523169A5 JP 2021523169 A5 JP2021523169 A5 JP 2021523169A5 JP 2020563505 A JP2020563505 A JP 2020563505A JP 2020563505 A JP2020563505 A JP 2020563505A JP 2021523169 A5 JP2021523169 A5 JP 2021523169A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- ch2oc
- och3
- sch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667540P | 2018-05-06 | 2018-05-06 | |
| US62/667,540 | 2018-05-06 | ||
| PCT/US2019/030771 WO2019217250A1 (en) | 2018-05-06 | 2019-05-05 | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523169A JP2021523169A (ja) | 2021-09-02 |
| JP2021523169A5 true JP2021523169A5 (enExample) | 2022-04-19 |
| JP7522661B2 JP7522661B2 (ja) | 2024-07-25 |
Family
ID=68468208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563505A Active JP7522661B2 (ja) | 2018-05-06 | 2019-05-05 | ビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210244745A1 (enExample) |
| EP (1) | EP3790552A4 (enExample) |
| JP (1) | JP7522661B2 (enExample) |
| KR (1) | KR20210005714A (enExample) |
| CN (1) | CN112218639A (enExample) |
| AU (2) | AU2019266150A1 (enExample) |
| BR (1) | BR112020022654A2 (enExample) |
| CA (1) | CA3099479A1 (enExample) |
| IL (1) | IL278492B2 (enExample) |
| MX (1) | MX2020011826A (enExample) |
| SG (1) | SG11202011041YA (enExample) |
| WO (1) | WO2019217250A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019215585A1 (en) * | 2018-05-06 | 2019-11-14 | Ayala Pharmaceuticals Inc. | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| US20220339162A1 (en) * | 2018-05-06 | 2022-10-27 | Ayala Pharmaceuticals Inc. | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors |
| WO2022241095A1 (en) * | 2021-05-13 | 2022-11-17 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer |
| SG11202011327UA (en) | 2018-05-15 | 2020-12-30 | Ayala Pharmaceuticals Inc | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma |
| EP3801551A4 (en) * | 2018-05-24 | 2022-04-06 | Ayala Pharmaceuticals Inc. | COMPOSITIONS WITH BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND IMMUNOTHERAPEUTICS AND METHODS OF USE THEREOF |
| EP3969001A4 (en) * | 2019-05-15 | 2023-02-22 | Ayala Pharmaceuticals Inc. | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF NOTCH-ACTIVATED BREAST CANCER |
| EP4337204A4 (en) * | 2021-05-13 | 2025-04-16 | Ayala Pharmaceuticals Inc. | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCER |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| TWI530489B (zh) * | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| US20140357605A1 (en) * | 2012-03-22 | 2014-12-04 | Bristol-Myers Squibb Company | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| EP2861255B1 (en) * | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| JP2015531792A (ja) * | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | １，４−ベンゾジアゼピノン化合物のプロドラッグ |
| EP2981267A1 (en) * | 2013-04-04 | 2016-02-10 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
| WO2015082583A1 (en) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| ES2808153T3 (es) * | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| ES3057783T3 (en) * | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| JP6911047B2 (ja) * | 2016-04-12 | 2021-07-28 | イーライ リリー アンド カンパニー | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
| US20190185559A1 (en) * | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| MX2019009552A (es) * | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| EP3615055A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US11970542B2 (en) * | 2017-11-08 | 2024-04-30 | Fred Hutchinson Cancer Center | Bispecific antibodies specific for treating hematological malignancies |
-
2019
- 2019-05-05 KR KR1020207034548A patent/KR20210005714A/ko not_active Ceased
- 2019-05-05 CN CN201980036073.7A patent/CN112218639A/zh active Pending
- 2019-05-05 SG SG11202011041YA patent/SG11202011041YA/en unknown
- 2019-05-05 WO PCT/US2019/030771 patent/WO2019217250A1/en not_active Ceased
- 2019-05-05 JP JP2020563505A patent/JP7522661B2/ja active Active
- 2019-05-05 IL IL278492A patent/IL278492B2/en unknown
- 2019-05-05 US US17/052,812 patent/US20210244745A1/en not_active Abandoned
- 2019-05-05 EP EP19800442.6A patent/EP3790552A4/en not_active Withdrawn
- 2019-05-05 AU AU2019266150A patent/AU2019266150A1/en not_active Abandoned
- 2019-05-05 MX MX2020011826A patent/MX2020011826A/es unknown
- 2019-05-05 CA CA3099479A patent/CA3099479A1/en active Pending
- 2019-05-05 BR BR112020022654-8A patent/BR112020022654A2/pt not_active Application Discontinuation
-
2020
- 2020-10-22 US US17/077,857 patent/US12281085B2/en active Active
-
2025
- 2025-03-07 AU AU2025201674A patent/AU2025201674A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523169A5 (enExample) | ||
| JP2024543967A5 (enExample) | ||
| IL278492B2 (en) | Combination compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| JP2020517616A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| JP2021519783A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| JP2024507938A5 (enExample) | ||
| JP2020007311A5 (enExample) | ||
| JP2021522275A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| JP2024534014A5 (enExample) | ||
| JP2022545005A5 (enExample) | ||
| JP2009519249A5 (enExample) | ||
| JP2011524422A5 (enExample) | ||
| JP2022071077A5 (enExample) | ||
| JP2025502377A5 (enExample) | ||
| JP2022137237A5 (enExample) | ||
| JP2016512831A5 (enExample) | ||
| JP2016501838A5 (enExample) | ||
| JP2023530316A5 (enExample) | ||
| JP2024515809A5 (enExample) | ||
| JP2017524013A5 (enExample) | ||
| JP2018525425A5 (enExample) |